169 related articles for article (PubMed ID: 26683768)
1. MicroRNA-555 has potent antiviral properties against poliovirus.
Shim BS; Wu W; Kyriakis CS; Bakre A; Jorquera PA; Perwitasari O; Tripp RA
J Gen Virol; 2016 Mar; 97(3):659-668. PubMed ID: 26683768
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-134 regulates poliovirus replication by IRES targeting.
Bakre AA; Shim BS; Tripp RA
Sci Rep; 2017 Oct; 7(1):12664. PubMed ID: 28978937
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA screening identifies miR-134 as a regulator of poliovirus and enterovirus 71 infection.
Orr-Burks NL; Shim BS; Wu W; Bakre AA; Karpilow J; Tripp RA
Sci Data; 2017 Mar; 4():170023. PubMed ID: 28248924
[TBL] [Abstract][Full Text] [Related]
4. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
5. Development of a multiplex RT-PCR assay for the identification of recombination types at different genomic regions of vaccine-derived polioviruses.
Dimitriou TG; Kyriakopoulou Z; Tsakogiannis D; Fikatas A; Gartzonika C; Levidiotou-Stefanou S; Markoulatos P
Virus Genes; 2016 Aug; 52(4):453-62. PubMed ID: 27098645
[TBL] [Abstract][Full Text] [Related]
6. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
7. Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.
van der Sanden SM; Wu W; Dybdahl-Sissoko N; Weldon WC; Brooks P; O'Donnell J; Jones LP; Brown C; Tompkins SM; Oberste MS; Karpilow J; Tripp RA
J Virol; 2016 Feb; 90(4):1694-704. PubMed ID: 26581994
[TBL] [Abstract][Full Text] [Related]
8. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.
Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L
BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521
[TBL] [Abstract][Full Text] [Related]
10. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
11. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
[TBL] [Abstract][Full Text] [Related]
12. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
13. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
[TBL] [Abstract][Full Text] [Related]
14. Restriction of poliovirus RNA replication in persistently infected nerve cells.
Girard S; Gosselin AS; Pelletier I; Colbère-Garapin F; Couderc T; Blondel B
J Gen Virol; 2002 May; 83(Pt 5):1087-1093. PubMed ID: 11961263
[TBL] [Abstract][Full Text] [Related]
15. Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection.
Arita M; Wakita T; Shimizu H
J Virol; 2012 May; 86(10):5541-53. PubMed ID: 22379090
[TBL] [Abstract][Full Text] [Related]
16. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.
Furione M; Guillot S; Otelea D; Balanant J; Candrea A; Crainic R
Virology; 1993 Sep; 196(1):199-208. PubMed ID: 8102826
[TBL] [Abstract][Full Text] [Related]
17. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
18. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
19. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.
Barnes D; Kunitomi M; Vignuzzi M; Saksela K; Andino R
Cell Host Microbe; 2008 Sep; 4(3):239-48. PubMed ID: 18779050
[TBL] [Abstract][Full Text] [Related]
20. Poliovirus vaccine strains in sewage and river water in South Africa.
Pavlov DN
Can J Microbiol; 2006 Aug; 52(8):717-23. PubMed ID: 16917529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
